Corbus Pharmaceuticals Holdings, Inc. (CRBP) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 21.48M USD | Liabilities, Current |
| Cash and equivalents | 23.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $21.48M | $23.37M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $18.14M | $25.66M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $20.69M | $28.49M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $17.06M | $26.98M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $13.33M | $20.04M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $11.62M | $18.90M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $11.82M | $17.20M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $11.63M | $19.42M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $23.98M | $23.69M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $25.92M | $14.10M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $31.89M | $13.72M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $31.54M | $11.25M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $16.39M | $8.35M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $14.36M | $7.32M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $12.64M | $17.00M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $17.47M | $12.44M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $15.63M | $25.77M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $15.12M | $57.03M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $17.01M | $25.01M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $17.14M | $37.12M | $69.74M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $18.74M | $36.08M | $70.37M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $23.61M | $66.61M | $57.40M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $31.90M | $85.43M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $41.40M | $81.87M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $42.09M | $63.47M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $34.65M | $46.62M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $34.89M | $31.75M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $30.55M | $54.85M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $29.44M | $73.15M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $52.04M | $89.92M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $18.09M | $41.75M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $16.93M | $55.66M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $13.45M | $64.68M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $10.28M | $70.96M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $8.20M | $62.54M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $6.34M | $36.60M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $6.91M | $43.03M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $6.96M | $48.93M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $8.90M | $14.99M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.43M | $18.91M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $4.96M | $22.03M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $4.08M | $9.69M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $3.63M | $12.34M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.88M | $13.17M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $2.34M | $9.24M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $554.77K | $4.97M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $738.04K | $6.26M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $613.68K | $7.54M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $8.50M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $163.04K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $648.87K | $303.02K | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $331.27K | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $542.48K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |